Literature DB >> 5316913

A biological standard for measurement of blood coagulation Factor VIII activity.

D R Bangham, R Biggs, M Brozović, K W Denson, J L Skegg.   

Abstract

Because of the instability of Factor VIII (antihaemophilic factor) in plasma in vitro, and since evidence has accumulated that the level of activity varies significantly between samples of "fresh normal plasma", it is apparent that a stable biological standard is required.Two freeze-dried preparations of Factor VIII, one plasma and one concentrate preparation, were prepared and have been assayed in a collaborative trial by 20 laboratories in 9 countries.The laboratories used their own methods and altogether 248 assays were carried out. Comparison of materials of similar type gave precise estimates with all the methods used, but when materials dissimilar in type and in Factor VIII content were compared less precise results were obtained. Sources of variation, such as differences in method, differences between operators, and day-to-day variations, were analysed.Accelerated degradation tests, carried out on the freeze-dried plasma and concentrate preparations, showed that Factor VIII activity was sufficiently stable in the concentrate for it to be used as a long-term standard but that the Factor VIII activity was less stable in the plasma preparation.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5316913      PMCID: PMC2427930     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  16 in total

1.  Studies on the storage lability of human antihemophilic factor.

Authors:  T H SPAET; E S GARNER
Journal:  J Lab Clin Med       Date:  1955-07

2.  A concentrate of human antihaemophilic factor; its use in six cases of haemophilia.

Authors:  R A KEKWICK; P WOLF
Journal:  Lancet       Date:  1957-03-30       Impact factor: 79.321

3.  The stability of biological standards.

Authors:  N K JERNE; W L PERRY
Journal:  Bull World Health Organ       Date:  1956       Impact factor: 9.408

4.  Preparation and standardization of a stable AHF plasma.

Authors:  G M Thelin
Journal:  Thromb Diath Haemorrh       Date:  1968-07-31

5.  Human plasma and plasma fractions as sources of factor VIII (antihaemophilic factor).

Authors:  M Verstraete; P Olislaegers; H Van Itterbeek; P Waumans; A Lust
Journal:  Vox Sang       Date:  1969-04       Impact factor: 2.144

6.  Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.

Authors:  J G Pool; A E Shannon
Journal:  N Engl J Med       Date:  1965-12-30       Impact factor: 91.245

7.  Activated coagulation factors: in-vivo and in-vitro studies.

Authors:  J Niemetz; H L Nossel
Journal:  Br J Haematol       Date:  1969-04       Impact factor: 6.998

8.  Antihaemophilic globulin: preparation by an improved cryoprecipitation method and clinical use.

Authors:  D L Brown; R M Hardisty; M H Kosoy; C Bracken
Journal:  Br Med J       Date:  1967-04-08

9.  The purification of factor 8 (antihaemophilic globulin). II. Further purification and some properities of factor 8.

Authors:  S E Michael; G W Tunnah
Journal:  Br J Haematol       Date:  1966-03       Impact factor: 6.998

10.  The factor-8 activity in fresh and stored plasma.

Authors:  A E Preston
Journal:  Br J Haematol       Date:  1967-01       Impact factor: 6.998

View more
  1 in total

1.  Standardization of diagnostic materials. 3. Laboratory reagents and coagulation assay procedures.

Authors:  E A Loeliger
Journal:  Bull World Health Organ       Date:  1973-06       Impact factor: 9.408

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.